ATE518845T1 - Optische isomere eines iloperidon-metaboliten - Google Patents

Optische isomere eines iloperidon-metaboliten

Info

Publication number
ATE518845T1
ATE518845T1 AT02767454T AT02767454T ATE518845T1 AT E518845 T1 ATE518845 T1 AT E518845T1 AT 02767454 T AT02767454 T AT 02767454T AT 02767454 T AT02767454 T AT 02767454T AT E518845 T1 ATE518845 T1 AT E518845T1
Authority
AT
Austria
Prior art keywords
optical isomers
iloperidone metabolite
fouoro
isoxazol
piperidin
Prior art date
Application number
AT02767454T
Other languages
German (de)
English (en)
Inventor
Dominique Grimler
Hans Kalkman
Hequn Yin
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE518845T1 publication Critical patent/ATE518845T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AT02767454T 2001-08-31 2002-08-30 Optische isomere eines iloperidon-metaboliten ATE518845T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31639001P 2001-08-31 2001-08-31
PCT/EP2002/009700 WO2003020707A1 (en) 2001-08-31 2002-08-30 Optical isomers of an iloperidone metabolite

Publications (1)

Publication Number Publication Date
ATE518845T1 true ATE518845T1 (de) 2011-08-15

Family

ID=23228843

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02767454T ATE518845T1 (de) 2001-08-31 2002-08-30 Optische isomere eines iloperidon-metaboliten

Country Status (9)

Country Link
US (4) US20050020632A1 (enExample)
EP (2) EP2305656B1 (enExample)
JP (6) JP2005504783A (enExample)
AT (1) ATE518845T1 (enExample)
CY (2) CY1112039T1 (enExample)
DK (2) DK1425272T3 (enExample)
ES (2) ES2398434T3 (enExample)
PT (2) PT2305656E (enExample)
WO (1) WO2003020707A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2463158C (en) 2001-10-30 2013-07-30 Novartis Ag Depot formulations of iloperidone and a star polymer
ATE398108T1 (de) 2002-03-27 2008-07-15 Glaxo Group Ltd Chinolinderivate und deren verwendung als 5-ht6 liganden
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
HRP20060100T3 (en) 2003-07-22 2007-03-31 Arena Pharmaceuticals Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
EP1799865B1 (en) 2004-09-30 2012-06-06 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
US20100063093A1 (en) 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
US20070262395A1 (en) 2006-05-11 2007-11-15 Gibbons Jasper S Memory cell access devices and methods of making the same
US8008144B2 (en) 2006-05-11 2011-08-30 Micron Technology, Inc. Dual work function recessed access device and methods of forming
BRPI0711872A2 (pt) * 2006-05-22 2011-12-06 Vanda Pharmaceuticals Inc tratamento para distúrbios depressivos
US20150259747A1 (en) 2007-03-29 2015-09-17 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation
EP2134873B1 (en) 2007-03-29 2015-05-06 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation
US8198305B2 (en) 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
US9080214B2 (en) 2007-05-18 2015-07-14 Vanda Pharmaceuticals, Inc. Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
US8652776B2 (en) 2007-09-10 2014-02-18 Vanda Pharmaceuticals, Inc. Prediction of QT prolongation based on SNP genotype
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
US8729100B2 (en) * 2007-12-13 2014-05-20 Vanda Pharmaceuticals, Inc. Method and composition for treating an alpha adrenoceptor-mediated condition
HRP20140701T1 (hr) 2007-12-13 2014-11-21 Vanda Pharmaceuticals Inc. Metoda i spoj za lijeäśenje stanja posredovanih serotoninskim receptorom
US20110061014A1 (en) 2008-02-01 2011-03-10 Energyhub Interfacing to resource consumption management devices
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
US7824986B2 (en) 2008-11-05 2010-11-02 Micron Technology, Inc. Methods of forming a plurality of transistor gates, and methods of forming a plurality of transistor gates having at least two different work functions
CA2757717C (en) 2009-04-06 2018-09-04 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to qt prolongation
WO2010117941A1 (en) 2009-04-06 2010-10-14 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to qt prolongation based on abcc2 gene sequence or product thereof
EP3354753B1 (en) 2009-04-06 2020-02-12 Vanda Pharmaceuticals Inc. Method of treatment based on polymorphisms of the kcnq1 gene
WO2010117943A1 (en) 2009-04-06 2010-10-14 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to qt prolongation based on bai3 gene sequence or product thereof
MX2012007365A (es) 2009-12-23 2012-08-15 Lupin Ltd Composiciones farmaceuticas de liberacion lenta de iloperidona.
WO2012032532A1 (en) * 2010-09-07 2012-03-15 Symed Labs Limited "processes for the preparation of 4'-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino]propoxy]-3'-methoxyacetophenone and intermediates thereof"
WO2012063269A2 (en) 2010-11-12 2012-05-18 Cadila Healthcare Limited Process for preparing iloperidone
EP2825167B1 (en) 2012-03-14 2018-05-09 Vanda Pharmaceuticals Inc. An iloperidone metabolite for use in the treatment of psychiatric disorders
US10441580B2 (en) 2015-02-17 2019-10-15 Vanda Pharmaceuticals, Inc. Iloperidone for the treatment of schizophrenia
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
IL285721B2 (en) 2019-02-21 2025-03-01 Obi Pharma Inc Methods of making high enantioselective secondary alcohols
US11607408B2 (en) 2019-10-15 2023-03-21 Vanda Pharmaceuticals Inc. Method of treatment of schizophrenia
EP4507698A1 (en) 2022-04-13 2025-02-19 Vanda Pharmaceuticals Inc. Treatment of parkinson's disease and parkinson's disease psychosis
CN120390640A (zh) 2022-12-19 2025-07-29 万达制药公司 治疗双相i型障碍和精神分裂症的伊潘立酮的给药方案
WO2024249952A1 (en) 2023-06-02 2024-12-05 Vanda Pharmaceuticals Inc. Method of treatment with iloperidone

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
ES2076253T3 (es) 1989-05-19 1995-11-01 Hoechst Roussel Pharma N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos.
JPH05286868A (ja) 1992-04-03 1993-11-02 Kiyoshi Okawa 制がん剤複合体およびそのスクリーニング法
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
ES2149742T1 (es) * 1997-07-03 2000-11-16 Asahi Chemical Ind Nuevos compuestos triciclicos que tienen anillos saturados y composiciones medicinales que contienen los mismos.
MXPA05000294A (es) 2002-07-30 2005-08-19 Peter Migaly Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.

Also Published As

Publication number Publication date
HK1156309A1 (en) 2012-09-07
DK2305656T3 (da) 2013-02-11
HK1066536A1 (en) 2005-03-24
EP2305656B1 (en) 2012-10-24
ES2370634T3 (es) 2011-12-21
JP2005504783A (ja) 2005-02-17
PT2305656E (pt) 2013-01-10
CY1113550T1 (el) 2016-06-22
US20130296366A1 (en) 2013-11-07
US7977356B2 (en) 2011-07-12
EP1425272B1 (en) 2011-08-03
US20110201646A1 (en) 2011-08-18
JP2015227368A (ja) 2015-12-17
US8314129B2 (en) 2012-11-20
ES2398434T3 (es) 2013-03-19
ES2398434T8 (es) 2017-10-09
DK1425272T3 (da) 2011-11-21
US20090176739A1 (en) 2009-07-09
EP1425272A1 (en) 2004-06-09
JP2013227335A (ja) 2013-11-07
PT1425272E (pt) 2011-10-19
JP2015214577A (ja) 2015-12-03
WO2003020707A1 (en) 2003-03-13
CY1112039T1 (el) 2015-11-04
JP2010100633A (ja) 2010-05-06
EP2305656A1 (en) 2011-04-06
JP2013116905A (ja) 2013-06-13
US20050020632A1 (en) 2005-01-27

Similar Documents

Publication Publication Date Title
ATE518845T1 (de) Optische isomere eines iloperidon-metaboliten
PE20080360A1 (es) Derivados 4-bencilftalazinona 2-sustituidos como antagonistas de histaminas h1 y h3
JP2010519243A5 (enExample)
NO20051965D0 (no) Nye piperidinderivater for anvendelse ved behandling av kemokinmedierte sykdomstilstander.
NO20062370L (no) Amidderivater
NO341632B1 (no) Ny polymorf form av 5-klor-N({(5S)-2-okso-3[4-(3-okso-4-morfolinyl)-fenyl]-1,3-oksazolidin-5-yl}-metyl)-2-tiofenkarboksamid
HRP20130174T1 (hr) Derivati pirimidina za lijeäśenje astme, kopb, alergijskog rinitisa, alergijskog konjuktivitisa, atopijskog dermatitisa, karcinoma, hepatitisa b, hepatitisa c, hiv, hpv, bakterijskih infekcija i dermatoze
TW200744994A (en) Insecticidal 3-acylaminobenzanilides
RU2010134361A (ru) Производные изоксазола в качестве модуляторов 11-бета-гидроксистероиддегидрогеназы 1 типа
ATE544756T1 (de) Substituierte carbinolverbindungen
PE20091431A1 (es) Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica
ATE455103T1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
HRP20080446T3 (en) Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine
NO20065327L (no) Fremgangsmate for fremstilling av derivarer av 5-'4-(2-hydroksy-propyl)-3,5-dihydro-3H'1, 2,4(triazin-2-yl)-benzamid.
RU2333204C2 (ru) Производные хинолинона/бензоксазинона и их применение
AR049699A1 (es) Derivados de pirimidina
JP2010143943A5 (enExample)
ATE476431T1 (de) Piperidin- und azetidinderivate als glyt1- inhibitoren
DE602004009079D1 (de) Carbostyril-derivative zur beschleunigten speichelabsonderung
RU2503674C2 (ru) Замещенные производные сульфонамида
NO20051089L (no) Bredspektrede 2-amino-benzotiazol-sulfonamid-HIV-proteaseinhibitorer
NO20070972L (no) Benzyloksyderivater som MAOB-inhibitorer
WO2007066163A3 (en) Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates
DE602006010329D1 (de) Verfahren zur herstellung eines indolon-derivats
UY31400A1 (es) Composiciones farmaceuticas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1425272

Country of ref document: EP